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Background: Metaplastic carcinoma of the breast (MCB) is a rare histological type of breast cancer. This study
aimed to determine whether MCB exhibits shorter overall survival (OS) and disease-free survival (DFS) compared
with other histologies that are considered unfavorable.
Methods: We retrospectively analyzed 157 clinical file records of the Mexico City-based National Institute of
Cancerology and compared the clinical characteristics and treatment of 24 patients with MCB, 37 patients with
triple-negative invasive lobular carcinoma (TN-ILC), 48 patients with high-grade invasive ductal carcinoma (HG-IDC),
and 48 patients with triple-negative invasive ductal carcinoma (TN-IDC), paired by clinical stage and age. We
performed a comparative analysis and analyzed OS and DFS using a log-rank test.
Results: In patients with MCB, the 5-year DFS was 52.1% (mean, 48.52 months; 95%: 35.32-61.72), and the 5-year
OS was 72.2% (mean, 59.77 months; 95% CI: 48.55-71.00). No differences were observed in the DFS of MCB compared
with each of the other histologies (MCB vs. HG-IDC, p = 0.865; MCB vs. TN-IDC, p = 0.966, and MCB vs. TN-ILC, p = 0.132).
Moreover, no differences were observed when comparing the OS of MCB with that of each of the other histologies
(MCB vs. HG-IDC, p = 0.246; MCB vs. TN-IDC, p = 0.255, and MCB vs. TN-ILC, p = 0.387).
Conclusions: Neither OS nor DFS differ between patients with MCB and those with other histologies with unfavorable
immunohistochemical factors.
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Breast cancer (BC) is the most common malignant
neoplasia in women in Mexico in terms of incidence and
mortality [1,2]. Approximately 85% of BC cases involve
invasive ductal carcinoma (IDC) or invasive lobular
carcinoma (ILC). The remaining 15% of cases include
other types of BC with specific differentiation, including
metaplastic carcinoma of the breast (MCB) [3].
The term MCB was introduced by Huvos et al. in
1973 [4]. MCB is characterized by a heterogeneous
mixture of two or three histological lineages [5,6], including
adenocarcinoma and other epithelial or mesenchymal* Correspondence: dcantude@gmail.com
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article, unless otherwise stated.components [7,8]. Among all of the BC types diagnosed
annually, MCB represents [9] approximately 0.25-1% [8-19].
Generally, MCB exhibits no characteristic pattern in
imaging studies, is characterized by rapid growth, and
requires additional immunohistochemical (IHC) studies
for its adequate characterization [5,8,11,12]. In most cases,
MCB has a triple-negative (TN) IHC profile [20-25],
resulting in a less-favorable prognosis [12,13,20,22,26].
Optimal management of a patient with a BC diagnosis
depends on the patient’s clinical characteristics, histology,
and the tumor’s IHC profile [22,27]. Management can
include surgery and radiotherapy (RT) for local control
[4,9,13]. The use of systemic chemotherapy (CT) has been
reported with discouraging results [8,16,28]. The clinico-
pathologic characteristics and prognosis of MCB, comparedCentral. This is an Open Access article distributed under the terms of the
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[7,8,24,29,30]. Some reports comparing the prognosis of
MCB with those of other BC types suggest that MCB is
more aggressive [7,12,22,24,29,31,32]. However, other
reports have indicated that the prognosis of MCB is
similar to that of adenocarcinoma [8,29].
This study aimed to determine whether an MCB
diagnosis confers poor prognosis with respect to overall
survival (OS) and disease-free survival (DFS) compared
with other common histologies that are considered un-
favorable (high-grade invasive ductal carcinoma [HG-IDC],
triple-negative invasive ductal carcinoma (TN-IDC), and
triple-negative invasive lobular carcinoma [TN-ILC]).
Methods
Patients were selected from the database of the
Mammary Tumors Department of the National Institute
of Cancerology (INCan) in Mexico City between January
2005 and January 2013. We obtained the clinical file
records of female patients diagnosed with MCB, IDC, or
ILC using conventional histology by one of the authors.
We excluded all patients with mixed histologies, those
with a diagnosis of carcinoma in situ, those whose clinical
file was incomplete, and those who had another histology
or synchronous tumors in another organ.
From the IDC patient group, we created two subgroups,
one defined as HG-IDC, to which patients with Scarff-
Bloom-Richardson grading system 8 and 9 were assigned,
and another group who had an IHC report of TN (estrogen
receptors [ER] and progesterone receptors [PR] with
nuclear staining of <1%, human epidermal receptor
[HER2/neu] with IHC of ≤1, or fluorescence in situ
hybridization at a ratio of HER2:centromere enumerator
probe [CEP] 17 of <1.8). We paired subjects by age and
clinical stage (CS), selecting two subjects for each type of
MCB case. From the ILC patient group, we included clas-
sic and pleomorphic variants and selected patients with an
IHC report of TN as previously described.
We obtained and analyzed the following variables: age;
tumor size; lymph node status; distant metastasis; CS; the
presence of hormonal receptors (HRs) and HER2/neu; use
of induction therapy; pathological response; surgery
performed; adjuvant therapy; and recurrence, progression
and survival of the patients through the last follow-up
appointment or date of death. For this final variable,
we located patients or spoke with a family member
by telephone to determine the patient’s status.
We conducted descriptive statistics for the demo-
graphic variables and report central tendency measures.
We conducted univariate analysis of means using Student’s
t test for continuous variables and the chi-square or Fisher
exact test for ordinal variables.
We calculated the follow-up of each patient. DFS
was defined as the period between the date at whichthe patient’s initial multimodal treatment (surgical, radio-
therapeutic, and/or systemic) terminated and the date of
recurrence or the patient’s last appointment. Recurrence
was defined as the presence of disease >6 months after
final treatment. Progression was defined as the presence of
disease 6 months before treatment was finalized. OS was
defined as the period between the date treatment ended
and the date of the patient’s last appointment or death.
DFS and OS were analyzed by the Kaplan-Meier
survival curve method, and the curves were compared
using the log-rank test. We performed multivariate
analysis to ascertain which variables exerted an influence
on OS and DFS using the Cox proportional hazards
model. Statistical significance was defined as a p value
of <0.05. We used the statistical software program
SPSS® 2012 for Windows (SPSS Inc., Austin, TX, USA) for
data analysis. The Director of Research of the INCan gave
ethical approval for the collection and use of the data for
this study.
This study was reviewed and approved by the Institutional
Review Board of the National Cancer Institute of Mexico
(approval number REV/20/14), and has been performed in
compliance with the Helsinki Declaration. Since this study
collected only archived data and materials, without using
personal data from patients, we were not required by our
federal legislation to obtain an informed consent from
patients, as well as for phone calls, when preservation of
confidentiality is assured. During the telephone call, the
patient or the family member that answered was informed
that a retrospective analysis was being performed and that
the actual status was necessary for completing the informa-
tion, also was established that all information will be kept
confidential in accordance to the legislation and will be used
only for this evaluation.
Results
We identified 32 (0.6%) patients with a diagnosis of
MCB among 5,440 patients diagnosed with BC. Of these
32 patients, we excluded 8 due to incomplete clinical
records or having mixed histologies, resulting in a total
of 24 patients for the final analysis. Of a total of 487
patients with an ILC diagnosis, we obtained 37 (7.6%)
patients with TN-ILC. The patients with MCB were
paired by age and CS at a ratio of 1:2 with patients with
HG-IDC and TN-IDC, resulting in 48 patients for each
group. All of the patients’ general clinicopathological
characteristics are described in Table 1. We analyzed 157
patients in total, with an average follow-up of 40 months
(range, 2.3-97.5 months).
The 24 patients with a diagnosis of MCB had an average
follow-up of 32.8 months (range, 4.1-73.4 months). The
mean patient age was 49.6 years (range, 33-86 years).
Three patients (12.5%) were grade IIA, 6 (25%) each were
grade IIB, IIIA, and IIIB, 1 patient (4.2%) was grade IIIC,
Table 1 Clinical and pathological characteristics of patients
MCB n (%) TN-ILC n (%) HG-IDC n (%) TN-IDC n (%) p value
Number of cases 24 37 48 48
Age Mean 49.58 53.49 49.25 49.52 0.478
CS I 0 0 0 0 0.364
IIA 3 (12.5) 4 (10.8) 6 (12.5) 6 (12.5)
IIB 6 (25.0) 1 (2.7) 12 (25.0) 12 (25.0)
IIIA 6 (25.0) 13 (35.1) 12 (25.0) 12 (25.0)
IIIB 6 (25.0) 7 (18.9) 12 (25.0) 12 (25.0)
IIIC 1 (4.2) 6 (16.2) 2 (4.2) 2 (4.2)
IV 2 (8.3) 6 (16.2) 4 (8.3 4 (8.3)
T T1 0 0 0 0 0.114
T2 0 3 (8.1) 1 (2.1) 1 (2.1)
T3 9 (37.5) 11 (29.7) 17 (35.4) 19 (39.6)
T4 15 (62.5) 23 (62.2) 30 (62.5) 28 (58.3)
N N0 7 (29.2) 5 (13.5) 9 (18.8) 8 (16.7) 0.748
N1 8 (33.3) 10 (27.0) 19 (39.6) 18 (37.5)
N2 7 (29.2) 16 (43.2) 17 (35.4) 19 (39.6)
N3 2 (8.3) 6 (16.2) 3 (6.3) 3 (6.3)
M M0 22 (91.7) 28 (75.7) 44 (91.7) 44 (91.7) 0.323
M1 2 (8.3) 9 (24.3) 4 (8.3) 4 (8.3)
HR Estrogen 2 (8.3) — 29 (60.4) — <0.001
Progesterone 3 (12.5) — 26 (54.2) — <0.001
HER2/neu Positive 1 (4.2) — 14 (29.2) — <0.001
MCB: metaplastic carcinoma of the breast; TN-ILC: triple-negative invasive lobular carcinoma; HG-IDC: high-grade invasive ductal carcinoma; TN-IDC: triple-negative
invasive ductal carcinoma; CS: clinical stage; T: tumor size; N: lymph nodes; M: distant metastasis; HR: hormone receptors; HER2/neu: human epidermal growth
factor receptor 2; BC: breast cancer.
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tumors >2 cm in size. Seven patients (29%) had no axillary
lymph node metastases, and 2 patients (8.3%) had distant
metastasis. The 48 HG-IDC patients had a mean follow-
up of 48.3 months (range, 10.5-93.8 months), and the 48
TN-IDC patients had an average follow-up of 45.2 months
(range, 5.0-97.5 months). The 37 patients diagnosed
with TN-ILC had a mean follow-up of 34 months
(range, 2.3-82.2 months) and a mean age of 53.49 years
(range, 29-86 years). Table 2 presents the general charac-
teristics of the treatment and clinical response.
Tables 1 and 2 show the comparative analysis of the
four histologies. The presence of HR and HER2/neu
was more common in HG-IDC compared with MCB
(ER: 60.4 vs. 8.3%; p <0.001; PR: 54.2 vs. 12.5%; p <0.001;
HER2/neu: 29.2 vs. 4.2%; p <0.001). TN-IDC and HG-IDC
patients were more likely to receive induction CT com-
pared with TN-ILC and MCB patients (81.3, 79.2, 54.1,
and 50%, respectively; p = 0.003). Regarding the type of
pathological response, pathologic partial responses (pPR)
were achieved by 75%, 65%, 61.5%, and 16.7% of TN-ILC,
HG-IDC, TN-IDC, and MCB patients, respectively
(p <0.001); similarly, pathologic complete responses (pCR)were less common in TN-ILC patients (10%) compared
with HG-IDC (30%), TN-IDC (28.2%), and MCB patients
(25%). Patients with MCB were more likely to progress
during treatment compared with TN-ILC, TN-IDC, and
HG-IDC patients (50%, 10%, 5.1%, and 5%, respectively;
p <0.001). Among the MCB patients who experienced
progression during CT induction, 4 received 5-fluorouracil-
adriamycin-cyclophosphamide (FAC) plus paclitaxel and
cisplatin as a radiosensitizer plus radiotherapy; 2 received
only FAC and paclitaxel. In comparison, the patients who
experienced partial and complete pathological responses
were treated with FAC and paclitaxel. MRM was the
most frequently performed surgical procedure and
was performed in 91.7% of MCB patients, 79.2% of
HG-IDC patients, 77.1% of TN-IDC patients, and
64.9% of TN-ILC patients (p = 0.011). Patients with
TN-IDC received more adjuvant CT compared with
TN-ILC, MCB, and HG-IDC patients (75%, 59.5%,
45.8%, and 39.6%, respectively; p = 0.009). With respect to
RT, no differences were observed between MCB (32.4%),
HG-IDC (47.9%), TN-IDC (56.3%) and TN-ILC patients
(59.5%) (p = 0.705). In the MCB group, 3 patients (12.5%)
experienced recurrence, 2 visceral and 1 to bone, whereas
Table 2 Characteristics of treatment and response by histology
MCB n (%) TN-ILC n (%) HG-IDC n (%) TN-IDC n (%) p value
Amount received 24 37 48 48
Ind CT 12 (50) 20 (54.1) 38 (79.2) 39 (81.3) <0.003
Response pPR 2 (16.7) 15 (75) 26 (65) 24 (61.5) <0.001
pCR 3 (25.0) 2 (10.0) 12 (30) 11 (28.2)
Stable 1 (8.3) 1 (5) 0 2 (5.1)
Progression 6 (50) 2 (10) 2 (5) 2 (5.1)
Surgery BCS 0 0 3 (6.3) 7 (14.6) 0.011
MRM 22 (91.7) 24 (64.9) 38 (79.2) 37 (77.1)
No 2 (8.3) 13 (35.1) 7 (14.6) 4 (8.3)
Adjuvancy Received 14 (58.3) 26 (70.3) 37 (77.1) 29 (60.4) 0.245
CT 11 (45.8) 22 (59.5) 19 (39.6) 36 (75.0) 0.009
RT 14 (58.3) 22 (59.5) 23 (47.9) 27 (56.3) 0.705
Recurrence No 15 (62.5) 13 (35.1) 28 (58.3) 29 (60.4) 0.094
Recurrence 3 (12.5) 12 (32.4) 18 (37.5) 16 (33.3)
Progression 6 (25) 12 (32.4) 2 (4.2) 3 (6.3)
MCB: metaplastic carcinoma of the breast; TN-ILC: triple-negative invasive lobular carcinoma; HG-IDC: high-grade invasive ductal carcinoma; TN-IDC: triple-negative
invasive ductal carcinoma; Ind CT: induction of chemotherapy; pPR: pathologic partial response; pCR: pathologic complete response; BCS: breast-conserving
surgery; MRM: modified radical mastectomy; CT: adjuvant chemotherapy; RT: radiotherapy.
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loco-regional.
In patients with MCB, the 5-year DFS was 52.1%
(mean, 48.52 months; 95% CI: 35.32-61.72 months),
whereas the 5-year DFS was 55.4% for HG-IDC patients
(mean, 61.52 months; 95% CI: 50.2-72.85 months),
60.1% for TN-IDC patients (mean, 59.81 months; 95%
CI: 47.78-72.85 months), and 29.9% for TN-ILC patients
(mean, 36.13 months; 95% CI: 25.33-46.93 months)
(Table 3). When DFS was compared among all of the
histologies, no significant differences were observed
(p = 0.071) (Figure 1). The five-year OS was 72.2% for
MCB patients (mean, 59.77 months; 95% CI: 48.55-
71.00 months), 73.7% for HG-IDC patients (mean,
81.68 months; 95% CI: 73.38-89.98 months), 84.8%
for TN-IDC patients (mean, 85.87 months; 95% CI:
77.10-94.64 months), and 44.3% for TN-ILC patients
(mean, 56.68 months; 95% CI: 45.63-67.74 months)
(Table 3). When the OS of all of the histologies was
compared, significant differences were observed (p = 0.027).
However, when the OS of MCB was compared with
each of the histologies, no significant differences for
any of the comparisons were detected (MCB vs. HG-IDC,
p = 0.246; MCB vs. TN-IDC, p = 0.255, and MCB vs.
TN-ILC, p = 0.387) (Figure 2).
We conducted a multivariate analysis with using a
Cox proportional hazards model. In the comparative
analysis, a significant difference (p <0.05) was observed,
and none of the variables independently influenced
OS or DFS.Discussion
Presently, BC is the most common neoplasm diagnosed
in Mexico [2]; thus, infrequent histologies are observed
more frequently than in other countries. One such histo-
logical type is MCB, and little is known about the clinico-
pathological characteristics and prognosis of MCB. Table 4
depicts the most representative series comparing MCB with
other histologies.
In this study, MCB represented 0.6% of all BC diag-
nosed, a percentage similar to those reported in other
studies [5,7,10,11,22]. In our series, the mean age at diag-
nosis of MCB was >40 years, similarly to other studies
[5,7,8,10-12,22,24,30]. All of the MCB and other BC
patients exhibited tumors >5 cm. Furthermore, lymph
node metastasis was observed in the majority of cases,
and no difference in the rate of lymph node metastasis
was observed with respect to other histologies. This
finding can be explained by the nature of the study and
the fact that Mexican female patients tend to present at
an advanced stage. Previous studies have established that
MCB tends to be diagnosed with larger tumors [7,22].
However, Bae et al. found no difference in tumor size
between MCB and TN-IDC (p = 0.144) [33]. Lymph node
metastasis has been shown to be less frequent in MCB
[31,32], but not all studies have confirmed this observation
[22,33]. In our study, 8.3% of the patient with MCB exhib-
ited distant metastasis. However, our results with respect to
MCB are consistent with the literature [22,31,34].
MCB was less likely to exhibit HR expression, with ex-
pression detected in 0-17% of cases [15,16,22]. Mourad
Table 3 Univariate analysis of means of overall survival (OS) and disease-free survival (DFS) by histology
MCB TN-ILC HG-IDC TN-IDC General p value
OS in months (95% CI) 59.77 (48.55-71.00) 56.68 (45.63-67.74) 81.68 (73.38-89.98) 85.87 (77.10-94.64) 78.66 (72.64-84.68) 0.027
DFS in months (95% CI) 48.52 (35.32-61.72) 36.13 (25.33-46.93) 61.52 (50.20-72.85) 59.81 (47.78-71.84) 55.56 (48.86-62.26) 0.071
95% CI: 95% confidence interval; MCB: metaplastic carcinoma of the breast; TN-ILC: triple-negative invasive lobular carcinoma; HG-IDC: triple-negative invasive
ductal carcinoma; TN-IDC: triple-negative invasive ductal carcinoma, OS: overall survival; DFS: disease-free survival.
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to the absence of an extensive glandular component
[35]. Additionally, HER2/neu overexpression has been
described within a range of 4-16% [31,33]. In our
study, most patients with MBC were HR-negative or
HER2/neu-negative, unlike patients with HG-IDC. This
description is consistent with that of other studies [12].
Park et al. described that 84% of MCB cases were TN, as
were 20.1% of IDC cases (p <0.001) [34].
Due to the rarity of MCB, few studies have evaluated
the response to induction therapy [12,28]. In a series of
39 patients in which 9 patients were given induction CT, 8
exhibited progression, and all died due to the disease [28].
In our study, only half of the MCB patients received CT
induction. Of patients who had a response, 25% had a
pCR; however, 50% experienced progression during induc-
tion. In our institution, most patients who experience pro-
gression during induction CT have received radiotherapy
with cisplatin as a radiosensitizer. Importantly, most MCB
patients who exhibited progression had been treated with
FAC-paclitaxel and concomitant cisplatin and radiother-
apy, indicating that this histology responds poorly to thisFigure 1 Disease-free survival (DFS) by individual histology. Metaplast
carcinoma (HG-IDC), p = 0.865. MCB vs. triple-negative invasive ductal carcin
carcinoma (TN-ILC), p = 0.132.systemic treatment. This response may be associated
with the intrinsic characteristics of MCB. According
to Weigelt, MCB can be molecularly classified as
claudin-low and basal-like [36], implying a behavior and
systemic therapy response similar to those of MBC and
mesenchymal neoplasias [37].
The group in which more BCSs were conducted was the
TN-IDC group, followed by the HG-IDC group; notably,
neither MCB nor TN-ILC patients were submitted to
BCS, likely because these patients were diagnosed with
larger tumors and exhibited poorer responses to induction
CT. Song et al. also reported more mastectomies in MCB
patients relative to TN-IDC patients (92.7 vs. 80.92%;
p = 0.054) [32]; however, Bae et al. did not observe
this difference (78.7 vs. 66.1%; p = 0.09) [33]. Of the
patients who received adjuvant chemotherapy, nearly
50% received CT. This percentage can be explained
by the fact that the patients who received induction
CT were not included (Table 2). The percentage of
patients who received RT was similar, with a slightly higher
trend in MCB and TN-ILC compared with HG-IDC and
TN-IDC (Table 2), possibly because BCS was less frequentic carcinoma of the breast (MCB) vs. high-grade invasive ductal
oma (TN-IDC), p = 0.966. MCB vs. triple-negative invasive lobular
Figure 2 Overall survival (OS) by individual histology. Metaplastic carcinoma of the breast (MCB) vs. high-grade invasive ductal carcinoma
(HG-IDC), p = 0.246. MCB vs. triple-negative invasive ductal carcinoma (TN-IDC), p = 0.255. MCB vs. triple-negative invasive lobular carcinoma
(TN-ILC), p = 0.387.
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troversy in the literature concerning whether patients
with MCB tend to receive more RT than other histol-
ogies [31-33].
The mean DFS of MCB was 48.52 months, with a
5-year DFS of 52.1%. No significant differences were
observed in DFS between MCB and each of the other
histologies analyzed (Figure 2). The mean OS of patients
with MCB was 59.77 months, with a 5-year OS of
72.2%. When comparing the OS of the groups studied,
a difference was observed between the four groups
(p = 0.027). However, when comparing the OS of MCB
with each group, this difference was not detected
(Figure 1). In patients with MCB, mean OS decreased
to 40 months (72.2 and 73%, respectively); thus, patients
with MCB stop dying, whereas patients with TN-ILC
continue to do so (80-month OS of 72.2% vs. 44.3%,
respectively) (Figure 1). Notably, in our study, both
MCB and TN-ILC patients exhibited worse OS com-
pared with TN-IDC patients, making both histological
types a worse prognostic factor for the OS of patients
with breast cancer. Whether histology modifies OS
and DFS remains controversial. In the Bae et al. study, the
3-year DFS did not differ between patients with MCB and
TN-IDC (78.1% vs. 84.9%; p <0.001) [3]. Lai et al. found
that the 5-year DFS did not differ between MCB and
ILC as much as the 5-year OS (p = 0.289 and 0.132,
respectively) [31]. Song et al. reported that the prognosis
of MCB was worse than that of TN-IDC, with a 5-year OS
of 54.5% for MCB vs. 73.3% for TN-IDC (p <0.001) and a5-year DFS of 45.5% in MCB vs. 60.3% in TN-IDC
(p <0.001) [32]. Larger studies have been conducted
to compare MCB and other histologies, including
HR-negative patients with negative hormonal recep-
tors, using patient information from the Surveillance,
Epidemiology, and End Results from United States
[38,39]. Nelson et al. compared 1,011 patients with
MBC with 253,818 patients with IDC between 2001
and 2010; the authors also compared patients with
respect to hormone receptors status and a matching
analysis. The paper concludes that MBC conferred a
worse OS and disease-specific survival (DSS) at
5 years compared with IDC (71% vs. 88%, and 78%
vs. 93%, respectively), HR-negative cancers (71% vs.
81% and 77% vs. 85%, respectively), and the matched
group (72% vs. 79% and 79% vs. 85%, respectively)
[38]. The second study was performed by Wright et al.,
who compared 2,338 patients with MCB with 382,667
patients with IDC; additionally, 44,813 patients with ILC
were included. This study reported that patients with
MCB exhibited a worse OS compared with IDC (62.1% vs.
82.1%, p <0.001), including those who were HR-negative
(63.5% vs. 72.2%, p <0001); however, when the authors
compared MCB and ILC with negative receptors, no
difference was detected with respect to OS (63.5% vs.
59.5%, p >0.15) and DSS (71.3% vs. 72.2%, p >0.65), similar
to the TN-ILC and MCB findings in our study [39].
However, both studies compared cancers based only on
the hormone receptors status, without knowing the HER2/
neu status or type of CT applied.
Table 4 Comparison with related studies
Author Histology Age (years) CS % TN % QX % CT % RT % 5-year OS 5-year DFS
Jung et al. (2010) MCB n = 35 47.4 I 17.1 II 60.0 III 8.6 IV 8.6 X 1.0 80.0 MRM 48.6 BCS 51.4 No 0.0 88.6 71.4 62.8 41.8
IDC n = 2,839 48.3 I 41.7 II 42.6 III 13.7 IV 2.0 X 0.0 16.7 MRM 24.3 BCS 74.8 No 1.0 80.6 82.1 92 87.3
TN-IDC n = 473 48.1 I 40.4 II 46.5 III 11.2 IV 2.1 X 0.0 NA MRM 31.7 BCS 67.7 No 0.6 90.5 84.1 83.6 81.8
Bae et al. (2011) [33] MCB n = 47 47.0 I 23.4 II 70.2 III 6.4 93.6 MRM 21.3 BCS 78.7 89.4 80.9 NA 3 years 78.1
IDC n = 1,346 48.6 I 37.8 II 47.2 III 15.0 16.2 MRM 41.0 BCS 59.0 81 67.4 NA 3 years 91.9
TN-IDC n = 218 47.9 I 32.6 II 54.6 III 12.8 NA MRM 33.9 BCS 66.1 90.9 73.9 NA 3 years 84.9
Song et al. (2013) [32] MCB n = 55 ≤50 = 49.1%
>50 = 50.1%
I 7.3 II 54.6 III 29.1 X 9.1 67.3 MRM 92.7 BCS 7.7 48 49.1 54.5 45.5
IDC n = 767 ≤50 = 52.8%
>50 = 47.2%
I 14.0 II 54.6 III 29.1 X 6.7 18.4 MRM 82.5 BCS 17.5 81.7 23.1 85.1 71.2
TN-IDC n = 131 ≤50 = 58.0%
>50 = 42.0%
I 16.0 II 70.2 III 6.11 X 7.6 NA MRM 80.9 BCS 19.1 80.9 27.1 73.3 60.3
Nelson et al. (2014) [38] MCB n = 1,011 61 I 26.4 II 64.2 III 9.4 ER/PR (-) 77.8% MRM 53.0 BCS 47.0 NA 48.3 71 *71 NA
IDC n = 253,818 59 I 56.1 II 35.7 III 8.2 ER/PR (-) 21.3% MRM 38.3 BCS 61.7 NA 54.3 88 *81 NA
Wright et al. (2014) [39] MCB n = 2,338 NA I 25.6 II 55.7 III 12.6 IV 6.0 ER/PR (-) 79.0% NA NA NA 62.2 *63.5 NA
IDC n = 382,667 NA I 52.2 II 30.7 III 12.7 IV 4.3 ER/PR (-) 22.2% NA NA NA 81.2 *72.2 NA
ILC n = 44,813 NA I 41.9 II 33.1 III 18.8 IV 6.3 ER/PR (-) 3.8% NA NA NA 80.2 *59.5 NA
Barquet et al.
(Current study)
MCB n = 24 49.6 II 37.5 III 54.2 IV 8.3 83.6 MRM 91.7 BCS 0.0 No 8.3 ind CT 50.0 adj CT 45.8 58.3 72.2 52.1
HG-IDC n = 37 49.3 II 37.5 III 54.2 IV 8.3 40.0 MRM 79.2 BCS 6.3 No 14.6 ind CT 79.2 adj CT 39.6 47.9 73.7 55.4
TN-IDC n = 48 49.5 II 37.5 III 54.2 IV 8.3 NA MRM 77.1 BCS 14.6 No 8.3 ind CT 81.3 adj CT 75 56.3 84.8 60.1
TN-ILC n = 48 53.5 II 13.5 III 70.2 IV 16.2 NA MRM 64.9 BCS 0.0 No 35.1 ind CT 54.1 adj CT 59.5 59.5 44.3 29.9
CS: clinical stage; TN: triple negative; QX: type of surgery; CT: chemotherapy; RT: radiotherapy; OS: overall survival; DFS: disease-free survival; MCB: metaplastic carcinoma of the breast; IDC: invasive ductal carcinoma;
TN-IDC: triple-negative invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER/PR(-): negative estrogen and progesterone receptors; HG-IDC: high-grade invasive ductal carcinoma; TN-IDC: triple-negative invasive
ductal carcinoma; TN-ILC: triple-negative invasive lobular carcinoma; X: not known; NA: not applicable; MRM: modified radical mastectomy; BCS: breast conservative surgery; ind CT: induction chemotherapy:
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reported in the literature in Latin America and par-
ticularly in a Mexican population; furthermore, this is
the first study to compare MCB with TN-ILC. Our
study has several limitations, such as its retrospective
design, the number of MCB cases, the focus only on
IHC characteristics, and the relatively short mean
follow-up. Therefore, future studies should consider
the molecular characteristics of each of the tumors.
Conclusions
MCB is an infrequent entity and thus is rarely stud-
ied. MCB tends to exhibit less BCS, likely due to the
CS at which it is diagnosed, its TN receptors and
because it exhibits disease progression. However, our
study demonstrated that the OS and DFS in patients
with MCB do not differ from those of patients with
the most common BC histologies with poor IHC pro-
files. Future studies should determine whether the
molecular characteristics contribute to the prognosis
of this type of BC.
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